MYGN Myriad Genetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MYGN

Price (delayed)

$16.27

Market cap

$1.33B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.04

Enterprise value

$1.43B

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing ...

Highlights
Myriad Genetics's revenue has increased by 4% YoY
The debt has soared by 102% YoY and by 26% from the previous quarter
The company's net income has shrunk by 70% QoQ
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.myriad.com/
Peers: BMRN EXAS BIOC BIO

Key stats

What are the main financial stats of MYGN
Market
Shares outstanding
81.88M
Market cap
$1.33B
Enterprise value
$1.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.8
Price to sales (P/S)
1.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.05
Earnings
Revenue
$698.9M
EBIT
-$262.3M
EBITDA
-$191M
Free cash flow
-$118.2M
Per share
EPS
-$3.04
Free cash flow per share
-$1.45
Book value per share
$9.01
Revenue per share
$8.55
TBVPS
$6.62
Balance sheet
Total assets
$1.19B
Total liabilities
$452M
Debt
$203.8M
Equity
$735.2M
Working capital
$73.2M
Liquidity
Debt to equity
0.28
Current ratio
1.33
Quick ratio
1.06
Net debt/EBITDA
-0.53
Margins
EBITDA margin
-27.3%
Gross margin
68.3%
Net margin
-35.5%
Operating margin
-37.6%
Efficiency
Return on assets
-20.8%
Return on equity
-29.4%
Return on invested capital
-55.7%
Return on capital employed
-27.2%
Return on sales
-37.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MYGN stock price

How has the Myriad Genetics stock price performed over time
Intraday
1.75%
1 week
-4.29%
1 month
-8.08%
1 year
-10.65%
YTD
12.13%
QTD
-29.81%

Financial performance

How have Myriad Genetics's revenue and profit performed over time
Revenue
$698.9M
Gross profit
$477.6M
Operating income
-$263.1M
Net income
-$248.2M
Gross margin
68.3%
Net margin
-35.5%
The company's net income has shrunk by 70% QoQ
The net margin has plunged by 69% from the previous quarter
The operating income has shrunk by 58% YoY and by 57% QoQ
The company's operating margin has shrunk by 56% QoQ and by 52% YoY

Growth

What is Myriad Genetics's growth rate over time

Valuation

What is Myriad Genetics stock price valuation
P/E
N/A
P/B
1.8
P/S
1.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.05
The EPS has plunged by 69% from the previous quarter
The company's equity fell by 22% YoY and by 12% QoQ
MYGN's price to book (P/B) is 12% lower than its 5-year quarterly average of 2.0 and 12% lower than its last 4 quarters average of 2.0
The P/S is 31% lower than the 5-year quarterly average of 2.7 and 22% lower than the last 4 quarters average of 2.4
Myriad Genetics's revenue has increased by 4% YoY

Efficiency

How efficient is Myriad Genetics business performance
MYGN's return on equity has dropped by 80% since the previous quarter
Myriad Genetics's return on assets has shrunk by 70% QoQ
The return on invested capital has dropped by 64% since the previous quarter
The ROS has plunged by 59% from the previous quarter

Dividends

What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MYGN.

Financial health

How did Myriad Genetics financials performed over time
Myriad Genetics's total assets is 163% more than its total liabilities
The company's total liabilities has surged by 72% YoY and by 35% QoQ
The quick ratio has dropped by 60% year-on-year and by 23% since the previous quarter
The debt is 72% less than the equity
The debt to equity has soared by 155% year-on-year and by 47% since the previous quarter
The debt has soared by 102% YoY and by 26% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.